Cargando…

Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection

BACKGROUND: Age and herb-drug combination are risk factors for the severity of Xiyanping injection (XYP) associated adverse events (AEs). OBJECTIVE: To analyze risk factors contributing to the severity of XYP’s AEs using a variable importance for projection (VIP) method. METHODS: AEs related to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Rui, Chen, Zhao, Guan, Zhiyue, Zhao, Chen, Cui, Herong, Shang, Hongcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923652/
https://www.ncbi.nlm.nih.gov/pubmed/36782216
http://dx.doi.org/10.1186/s13020-023-00718-8
_version_ 1784887761255268352
author Zheng, Rui
Chen, Zhao
Guan, Zhiyue
Zhao, Chen
Cui, Herong
Shang, Hongcai
author_facet Zheng, Rui
Chen, Zhao
Guan, Zhiyue
Zhao, Chen
Cui, Herong
Shang, Hongcai
author_sort Zheng, Rui
collection PubMed
description BACKGROUND: Age and herb-drug combination are risk factors for the severity of Xiyanping injection (XYP) associated adverse events (AEs). OBJECTIVE: To analyze risk factors contributing to the severity of XYP’s AEs using a variable importance for projection (VIP) method. METHODS: AEs related to the use of XYP were extracted from the China National Adverse Drug Reaction Monitoring Information System (2004–2017) and classified as general or severe. Data were analyzed with respect to age and 12 herb-drug combinations, including ribavirin (RB), ceftriaxone, penicillin sodium, ambroxol hydrochloride (AH), clindamycin, cefoxitin sodium, azithromycin (AZM), ceftazidime, amoxicillin sodium/potassium clavulanate, levofloxacin hydrochloride, sodium cefazolin pentahydrate, and acyclovir according to VIP scores and correlation coefficient (Coeff). RESULTS: A total of 21,714 AEs (general 20,660; severe 1054) related to XYP combinations were included. Using XYP alone tended to produce general AEs (All VIP = 3.124; 1.329; 1.857; 2.169; 2.400, Coeff < 0). For all set, 0–6 years old patients tend to have general AEs (VIP = 2.425, Coeff < 0), while those > 41 years old patients tend to have severe AEs (VIP = 1.180; 2.323, Coeff > 0). For 0–40 years old patients, XYP-RB combination had a greater impact on the severity of AEs (VIP = 1.158; 1.360; 1.147, Coeff > 0). For 7–17 years old patients, XYP-AZM combination tended to produce general AEs (VIP = 1.502, Coeff < 0). In individuals > 65 years old, XYP-AH combination tended to result in severe AEs (VIP = 1.232, Coeff > 0). CONCLUSIONS: VIP method was expected to effectively analyze risk factors in affecting the severity of AEs and control AEs more effectively. Age is the key factor contributing to the severity of AEs, and there are different influence directions. It is recommended that clinicians pay closer attention to the metabolic characteristics of different age groups. It is safe to use XYP alone and strictly implementing standardized operations such as medication interval and flushing will avoid undesired AEs.
format Online
Article
Text
id pubmed-9923652
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99236522023-02-13 Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection Zheng, Rui Chen, Zhao Guan, Zhiyue Zhao, Chen Cui, Herong Shang, Hongcai Chin Med Research BACKGROUND: Age and herb-drug combination are risk factors for the severity of Xiyanping injection (XYP) associated adverse events (AEs). OBJECTIVE: To analyze risk factors contributing to the severity of XYP’s AEs using a variable importance for projection (VIP) method. METHODS: AEs related to the use of XYP were extracted from the China National Adverse Drug Reaction Monitoring Information System (2004–2017) and classified as general or severe. Data were analyzed with respect to age and 12 herb-drug combinations, including ribavirin (RB), ceftriaxone, penicillin sodium, ambroxol hydrochloride (AH), clindamycin, cefoxitin sodium, azithromycin (AZM), ceftazidime, amoxicillin sodium/potassium clavulanate, levofloxacin hydrochloride, sodium cefazolin pentahydrate, and acyclovir according to VIP scores and correlation coefficient (Coeff). RESULTS: A total of 21,714 AEs (general 20,660; severe 1054) related to XYP combinations were included. Using XYP alone tended to produce general AEs (All VIP = 3.124; 1.329; 1.857; 2.169; 2.400, Coeff < 0). For all set, 0–6 years old patients tend to have general AEs (VIP = 2.425, Coeff < 0), while those > 41 years old patients tend to have severe AEs (VIP = 1.180; 2.323, Coeff > 0). For 0–40 years old patients, XYP-RB combination had a greater impact on the severity of AEs (VIP = 1.158; 1.360; 1.147, Coeff > 0). For 7–17 years old patients, XYP-AZM combination tended to produce general AEs (VIP = 1.502, Coeff < 0). In individuals > 65 years old, XYP-AH combination tended to result in severe AEs (VIP = 1.232, Coeff > 0). CONCLUSIONS: VIP method was expected to effectively analyze risk factors in affecting the severity of AEs and control AEs more effectively. Age is the key factor contributing to the severity of AEs, and there are different influence directions. It is recommended that clinicians pay closer attention to the metabolic characteristics of different age groups. It is safe to use XYP alone and strictly implementing standardized operations such as medication interval and flushing will avoid undesired AEs. BioMed Central 2023-02-13 /pmc/articles/PMC9923652/ /pubmed/36782216 http://dx.doi.org/10.1186/s13020-023-00718-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zheng, Rui
Chen, Zhao
Guan, Zhiyue
Zhao, Chen
Cui, Herong
Shang, Hongcai
Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection
title Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection
title_full Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection
title_fullStr Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection
title_full_unstemmed Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection
title_short Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection
title_sort variable importance for projection (vip) scores for analyzing the contribution of risk factors in severe adverse events to xiyanping injection
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923652/
https://www.ncbi.nlm.nih.gov/pubmed/36782216
http://dx.doi.org/10.1186/s13020-023-00718-8
work_keys_str_mv AT zhengrui variableimportanceforprojectionvipscoresforanalyzingthecontributionofriskfactorsinsevereadverseeventstoxiyanpinginjection
AT chenzhao variableimportanceforprojectionvipscoresforanalyzingthecontributionofriskfactorsinsevereadverseeventstoxiyanpinginjection
AT guanzhiyue variableimportanceforprojectionvipscoresforanalyzingthecontributionofriskfactorsinsevereadverseeventstoxiyanpinginjection
AT zhaochen variableimportanceforprojectionvipscoresforanalyzingthecontributionofriskfactorsinsevereadverseeventstoxiyanpinginjection
AT cuiherong variableimportanceforprojectionvipscoresforanalyzingthecontributionofriskfactorsinsevereadverseeventstoxiyanpinginjection
AT shanghongcai variableimportanceforprojectionvipscoresforanalyzingthecontributionofriskfactorsinsevereadverseeventstoxiyanpinginjection